Callahan Catherine L, Schwartz Kendra, Ruterbusch Julie J, Shuch Brian, Graubard Barry I, Lan Qing, Cawthon Richard, Baccarelli Andrea A, Chow Wong-Ho, Rothman Nathaniel, Hofmann Jonathan N, Purdue Mark P
Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD 20850, USA.
Department of Family Medicine and Public Health Sciences, Karmanos Cancer Institute, Wayne State University, 3939 Woodward Ave., Detroit, MI 48201, USA.
Br J Cancer. 2017 Aug 22;117(5):752-755. doi: 10.1038/bjc.2017.237. Epub 2017 Jul 25.
Leukocyte telomere length (LTL) is a potential biomarker of cancer prognosis; however, evidence for renal cell carcinoma (RCC) is inconsistent.
We investigated LTL and RCC-specific survival among 684 cases from the US kidney cancer study (USKC) and 241 cases from the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO). Leukocyte telomere length was measured by quantitative polymerase chain reaction, and hazard ratios (HRs) and 95% confidence intervals (CIs) computed using multivariable Cox models.
Short LTL was associated with poorer disease-specific survival in both USKC (lowest vs highest quartile: HR: 2.3, 95% CI: 1.2-4.4; P for trend=0.02) and PLCO (HR: 2.4, 95% CI: 1.0-5.4; P=0.04). Among USKC cases, the association was strongest for stage-I RCC (HR: 5.5, 95% CI: 1.6-19.0; P=0.006).
Our findings suggest that shorter LTL is an independent marker of poor RCC prognosis, particularly for stage-I disease.
白细胞端粒长度(LTL)是癌症预后的一个潜在生物标志物;然而,关于肾细胞癌(RCC)的证据并不一致。
我们调查了来自美国肾癌研究(USKC)的684例患者和来自前列腺、肺、结肠和卵巢癌筛查试验(PLCO)的241例患者的LTL和RCC特异性生存率。通过定量聚合酶链反应测量白细胞端粒长度,并使用多变量Cox模型计算风险比(HRs)和95%置信区间(CIs)。
在美国肾癌研究(USKC)(最低四分位数与最高四分位数相比:HR:2.3,95%CI:1.2 - 4.4;趋势P值 = 0.02)和前列腺、肺、结肠和卵巢癌筛查试验(PLCO)(HR:2.4,95%CI:1.0 - 5.4;P = 0.04)中,短LTL均与较差的疾病特异性生存率相关。在美国肾癌研究(USKC)病例中,这种关联在I期肾细胞癌中最为明显(HR:5.5,95%CI:1.6 - 19.0;P = 0.006)。
我们的研究结果表明,较短的LTL是肾细胞癌预后不良的独立标志物,特别是对于I期疾病。